Triple-Negative Breast Cancer with Dermatomyositis: A Case Report and Literature Review

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Vaidyanathan K. The challenge of triple negative breast cancers. Indian J Clin Biochem. 2014;29(3):267–268. doi:10.1007/s12291-014-0453-1
   PubMedGoogle Scholar
• Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–5657. doi:10.1200/JCO.2006.06.5664
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–4434. doi:10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Calderon LE, Black CA, Rollins JD, et al. Synthesis of radiolabeled technetium- and rhenium-luteinizing hormone-releasing hormone ((99m)Tc/Re-Acdien-LHRH) conjugates for targeted detection of breast cancer cells overexpressing the LHRH receptor. ACS Omega. 2021;6(3):1846–1856. doi:10.1021/acsomega.0c03991
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26–30. doi:10.1001/archdermatol.2009.328
   PubMedGoogle Scholar
• Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28(6):913–921. doi:10.1080/14397595.2018.1467257
   PubMed Web of Science ®Google Scholar
• Yang SH, Chang C, Lian ZX. Polymyositis and dermatomyositis - challenges in diagnosis and management. J Transl Autoimmun. 2019;2:100018. doi:10.1016/j.jtauto.2019.100018
   PubMedGoogle Scholar
• Piras M, Panebianco M, Garibaldi M, et al. A case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in HER2-positive early breast cancer. Curr Oncol. 2021;28(3):1957–1961. doi:10.3390/curroncol28030182
   PubMed Web of Science ®Google Scholar
• Chang L, Zhang L, Jia H, Nie Z, Zhang L. Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China. Medicine (Baltimore). 2020;99(34):e21733. doi:10.1097/MD.0000000000021733
   PubMed Web of Science ®Google Scholar
• Hendren E, Vinik O, Faragalla H, Haq R. Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol. 2017;24(5):e429–e33. doi:10.3747/co.24.3696
   PubMed Web of Science ®Google Scholar
• Cobos GA, Nelson CA, Alsarheed A, et al. Capecitabine-related eruption mimicking dermatomyositis in 2 patients with metastatic breast cancer. JAMA Dermatol. 2020;156(1):103–104. doi:10.1001/jamadermatol.2019.3162
   PubMed Web of Science ®Google Scholar
• Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One. 2014;9(4):e94128. doi:10.1371/journal.pone.0094128
   PubMed Web of Science ®Google Scholar
• Hu T, Vinik O. Dermatomyositis and malignancy. Can Fam Physician. 2019;65(6):409–411.
   PubMed Web of Science ®Google Scholar
• Alenzi FM. Myositis specific autoantibodies: a clinical perspective. Open Access Rheumatol. 2020;12:9–14. doi:10.2147/OARRR.S231195
   PubMed Web of Science ®Google Scholar
• DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82(2):267–281. doi:10.1016/j.jaad.2019.06.1309
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005;201(4):591–601. doi:10.1084/jem.20041367
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636–644. doi:10.1097/BOR.0000000000000329
   PubMed Web of Science ®Google Scholar
• Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev. 2010;9(6):449–453. doi:10.1016/j.autrev.2009.12.005
   PubMed Web of Science ®Google Scholar
• Primiano G, Plantone D, Sauchelli D, et al. Resolution of muscle inflammation after tumor removal in a woman with paraneoplastic dermatomyositis. J Rheumatol. 2012;39(12):2359–2360. doi:10.3899/jrheum.120806
   PubMed Web of Science ®Google Scholar
• Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008;7(5):352–358. doi:10.1016/j.autrev.2008.02.001
   PubMed Web of Science ®Google Scholar
• Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? Surg Oncol Clin N Am. 2018;27(1):141–153. doi:10.1016/j.soc.2017.08.004
   PubMed Web of Science ®Google Scholar
• Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: current concepts. Clin Dermatol. 2018;36(4):450–458. doi:10.1016/j.clindermatol.2018.04.003
   PubMed Web of Science ®Google Scholar
• Dias LP, Faria AL, Scandiuzzi MM, Inhaia CL, Shida JY, Gebrim LH. A rare case of severe myositis as paraneoplastic syndrome on breast cancer. World J Surg Oncol. 2015;13:134. doi:10.1186/s12957-015-0534-5
   PubMed Web of Science ®Google Scholar
• Sandhu NP, Zakaria S, Degnim AC, Boughey JC. Dermatomyositis presenting as a paraneoplastic syndrome due to underlying breast cancer. BMJ Case Rep. 2011;2011:bcr1020103416–bcr1020103416. doi:10.1136/bcr.10.2010.3416
   PubMedGoogle Scholar
• Inaguma G, Shimada A, Tsunoda J, et al. Inflammatory breast cancer associated with amyopathic dermatomyositis: a case report. Surg Case Rep. 2020;6(1):284. doi:10.1186/s40792-020-01066-7
   PubMed Web of Science ®Google Scholar
• Pellegrino B, Mazzaschi G, Madeddu D, et al. Clinico-immunological profile of a 67-year-old woman affected by HER2-positive breast cancer and autoimmune dermatomyositis. Front Oncol. 2020;10:192. doi:10.3389/fonc.2020.00192
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang C, Yang Z, et al. Male occult triple-negative breast cancer with dermatomyositis: a case report and review of the literature. Onco Targets Ther. 2017;10:5459–5462. doi:10.2147/OTT.S151260
   PubMed Web of Science ®Google Scholar
• Chen AM, Obedian E, Haffty BG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J. 2001;7(6):480–491.
   PubMed Web of Science ®Google Scholar